top of page
Search

Medical Device Companies Hits & Misses: 1.27-28.26

Updated: Feb 3

The "wait and see" era is over. This week’s earnings calls (Jan 27–28) confirmed a fundamental shift: The market is no longer rewarding medtech companies just for growing. It is rewarding them for resilience.


Check back throughout the coming weeks as I cover additional companies and the running comparison chart grows. Reach out to us directly if you have a company you'd like included: hello@allons-y.co


If you’re a CEO or CFO in this space, your 2026 playbook just changed. Here are three themes we’ve learned from this week's Q4 earnings cycle.


1. The "Tariff Trap" is the New Supply Chain Crisis

Supply chain issues used to be about availability. In 2026, they are about affordability. * The Reality Check: CONMED set a new standard by being the first to put a hard number on the "Trump 2.0" effect: a $0.30–$0.35 EPS hit from incremental tariffs.

  • The Strategic Move: Leading firms like Danaher are aggressively "reshoring" or moving to a "China-for-China" localized manufacturing model. Are you quantifying your tariff exposure for your board today?


2. AI: From "Hype" to "Hardware Productivity"

Investors are officially bored with "AI-enabled" as a marketing buzzword. They want to see compute power in the physical device that solves the #1 hospital problem: Labor shortages.

  • The Shift: Danaher isn't just talking about AI; they've appointed a Chief AI Officer and are embedding AI into their Xcellerex X-platform bioreactors to reduce the time and cost of biologic manufacturing.

  • The KPI: Does your AI save a lab tech 20 minutes? Does it prevent a clinical error? If yes, it’s a product. Make sure you leverage this as credit for strategic use of AI. If not, it’s just a feature and likely not driving the strategic advantage you are hoping for.


3. Aggressive Portfolio Pruning

The "Diversified Discount" is back. The market is rewarding companies that cut the "dead wood" to focus on high-margin, high-growth cores.

  • The Case Study: CONMED’s total exit from the Gastroenterology business is the headline move. It’s painful in the short term (diluting EPS by ~$0.50), but it immediately improves the company’s long-term gross margin by 80 basis points.

  • The Lesson: In a high-rate environment, "good enough" segments are a liability. Are you doing what it takes to shape your portfolio for resilient margin and growth outlook?


MedTech Performance Map: Q4 2025 Reporting Cycle

This list will continue to grow. Come back in the coming weeks for an update.



The Executive Playbook: 3 Actions for Monday Morning

  1. Quantify the Customs Line: Ask your CFO for a "Reciprocal Tariff" impact model. Use CONMED’s $0.30 EPS benchmark as your stress test.

  2. Audit the "Digital" Portfolio: If your AI doesn't directly offset a labor cost for a hospital, pivot that R&D toward embedded hardware automation.

  3. Prune the Tail: Look at your lowest-margin 10%. If a giant like CONMED is willing to exit a core segment like GI to protect the P&L, you should be too.


 
 
 

Comments

bottom of page